The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Glofitamab and polatuzumab vedotin in DLBCL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents findings from the open-label, Phase Ib/II trial (NCT03533283) trial of glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, with polatuzumab vedotin, an antibody-drug conjugate, in patients with diffuse large B-cell lymphoma (DLBCL). An encouraging safety profile was observed, with no cases of grade 3 or higher cytokine release syndrome (CRS) observed, which can be attributed to prior administration of obinutuzumab and polatuzumab vedotin. The treatment combination additionally demonstrated promising efficacy, with half of patients reporting a complete response. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
